[Some characteristics of the biological action of D, L-1,4-dibromo-1,4-dideoxy-2,3-butanediol].
In tests conducted on mice and rats with transplantable tumours the antineoplastic activity of the racemic agent D, L-1,4-dibromo-1, 4-didesoxy-2, 3-butandiol is shown. With chronic administration of the drug in subtherapeutic and therapeutic doses a higher leucocytes count was in evidence in the blood of the animals with and without tumours.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002072:Butylene Glycols / Q000494:pharmacology*; D002279:Carcinoma 256, Walker / Q000188:drug therapy; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D002296:Carcinosarcoma / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D007958:Leukocyte Count; D007962:Leukocytes / Q000187:drug effects; D008223:Lymphoma / Q000188:drug therapy; D051379:Mice; D009368:Neoplasm Transplantation; D051381:Rats; D012510:Sarcoma 180 / Q000188:drug therapy; D012511:Sarcoma 37 / Q000188:drug therapy; D012513:Sarcoma, Experimental / Q000188:drug therapy; D013997:Time Factors
D000970:Antineoplastic Agents; D002072:Butylene Glycols
Nekotorye osobennosti biologicheskogo deĭstviia D, L-1,4-dibrom-1,4-didezoksi-2, 3-butandiola